The FTIR spectrum of prostate cancer cells allows the classification of anticancer drugs according to their mode of action.

The number of anticancer agents that fail in the clinic far outweighs those considered effective, suggesting that the selection procedure for progression of drug molecules into the clinic requires improvement. Traditionally, new drugs are evaluated for their potential to kill cancer cell lines. This approach is obviously not sufficient, and molecules with new modes of action are required. We suggest here that the infrared spectrum of cells exposed to anticancer drugs could offer an opportunity to obtain a fingerprint of the metabolic changes induced by the drugs. Because the infrared spectrum of cells yields a precise image of all the chemical bonds present in the sample, different drug targets are likely to yield different infrared fingerprints characteristic of the 'mode of action' of the therapeutic agent under investigation. In turn, drug-induced metabolic disorders should be amenable to classification in the same way that bacteria gender, species, and strains can be classified. We examined here a human prostate cancer PC-3 cell line exposed to 7 well described antimitotics. In a first step the IC(50) values were determined. For FTIR imaging, PC-3 cells were exposed to the IC(50) concentration of each drug for 48 h. About one hundred images of 4096 IR spectra at 8 cm(-1) spectral resolution were acquired. We show with a Student t-test that the different molecules tested induced different infrared spectral modifications. Furthermore, drugs known to induce similar types of metabolic disturbances appear to cluster when spectrum shapes are analyzed. Finally, supervised statistical methods allowed the building of an efficient and discriminant model. When the discriminant model was applied to a full infrared image a good sorting was generally obtained and misclassified spectra generally belonged to a small number of specific cells. Taken all together these data suggest that FTIR could be used for the classification of drug action.

[1]  Max Diem,et al.  Microspectroscopy of single proliferating HeLa cells , 2005 .

[2]  B. Wood,et al.  FTIR microspectroscopic study of cell types and potential confounding variables in screening for cervical malignancies. , 1998, Biospectroscopy.

[3]  R. Kiss,et al.  The infrared spectrum of human glioma cells is related to their in vitro and in vivo behavior. , 2004, Experimental cell research.

[4]  Peter Lasch,et al.  In situ identification of protein structural changes in prion-infected tissue. , 2003, Biochimica et biophysica acta.

[5]  Chao-Liang Wu,et al.  Methotrexate conjugated to gold nanoparticles inhibits tumor growth in a syngeneic lung tumor model. , 2007, Molecular pharmaceutics.

[6]  Max Diem,et al.  Infrared Spectroscopy of Cells and Tissues: Shining Light onto a Novel Subject , 1999 .

[7]  Robert Kiss,et al.  IR spectroscopy as a new tool for evidencing antitumor drug signatures. , 2009, Biochimica et biophysica acta.

[8]  N. Clarke,et al.  Factors influencing the discrimination and classification of prostate cancer cell lines by FTIR microspectroscopy. , 2009, The Analyst.

[9]  E. Goormaghtigh,et al.  Attenuated total reflection infrared spectroscopy of proteins and lipids in biological membranes. , 1999, Biochimica et biophysica acta.

[10]  T. Mosmann.  Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.

[11]  D. Naumann,et al.  Classification and identification of bacteria by Fourier-transform infrared spectroscopy. , 1991, Journal of general microbiology.

[12]  D. Bertrand,et al.  Application of PLS‐DA in multivariate image analysis , 2006 .

[13]  Ganesh D. Sockalingum,et al.  IR spectroscopy reveals effect of non-cytotoxic doses of anti-tumour drug on cancer cells , 2009, Analytical and bioanalytical chemistry.

[14]  M. Bibby,et al.  50 years of preclinical anticancer drug screening: empirical to target-driven approaches. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  R. Kiss,et al.  FTIR spectral signature of the effect of cardiotonic steroids with antitumoral properties on a prostate cancer cell line. , 2010, Biochimica et biophysica acta.

[16]  P. Morris,et al.  Microtubule Active Agents: Beyond the Taxane Frontier , 2008, Clinical Cancer Research.

[17]  A. Negi,et al.  Plant-based anticancer molecules: a chemical and biological profile of some important leads. , 2005, Bioorganic & medicinal chemistry.

[18]  M. Diem,et al.  Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. , 1999, Biospectroscopy.

[19]  B. Rigas,et al.  Cytologically normal cells from neoplastic cervical samples display extensive structural abnormalities on IR spectroscopy: implications for tumor biology. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Goormaghtigh Erik,et al.  SUBTRACTION OF ATMOSPHERIC WATER CONTRIBUTION IN FOURIER TRANSFORM INFRARED SPECTROSCOPY OF BIOLOGICAL MEMBRANES AND PROTEINS , 1994 .

[21]  P. Choong,et al.  Review: doxorubicin delivery systems based on chitosan for cancer therapy. , 2009, The Journal of pharmacy and pharmacology.

[22]  J Dwyer,et al.  Fixation protocols for subcellular imaging by synchrotron‐based Fourier transform infrared microspectroscopy , 2005, Biopolymers.

[23]  D A Scudiero,et al.  Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. , 1988, Cancer research.

[24]  Harald Labischinski,et al.  Microbiological characterizations by FT-IR spectroscopy , 1991, Nature.